Abstract
Objective: To study the changes of thrombomodulin(TM) in both plasma and tissue extracts of cancer patients for evaluating its clinical significance.
Methods: Plasma TM levels were measured by enzyme-linked immunosorbent assay(ELISA) in both plasma of 188 cancer patients and 24 cancer tissue extracts including their adjacent non-cancer tissues.
Results: The plasma TM levels both in cancer patients and in metastasis patients were significantly higher than that in controls [(33.47±14.25)ug/L/(41.68±16.96)ug/L, vs (20.40±7.22)ug/L, P<0.01]. The plasma TM levels in cancer patients after operation decreased obviously than that before operation [(18.45±9.96)ug/L, vs (28.29±11.74)ug/L, P<0.01], whereas, the plasma TM levels in patients with recurrence and metastasis after operation increased obviously [(34.50±12.57)ug/L]. Among the type of cancer, the plasma TM levels in metastasis including lung cancers and gastric cancers and pancreatic cancers were significantly higher than that in non-metastasis respectively, but no significant differences were foundPOST http://www.call4abstracts.com/hem/body.pincluding gastric cancers and pancreatic cancers and nasopharyngeal cancers and large intestine cancers and laryngeal cancers (P>0.05). The TM levels in cancer tissue extracts were significantly lower than that in their adjacent non-cancer tissue extracts [(647.71±317.51)ug/L vs (1455.63±772.22)ug/L, P<0.01]. On the contrary, the plasma TM levels in these cancers were significantly higher than that in controls.
Conclusion: The rise of plasma TM levels in cancer patients was associated with metastasis and diffusion of cancers. The TM levels can be served as a sensitive index for judging progression and metastasis of cancers.
Author notes
Corresponding author
